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Abstract
In this account, we varied PEGylation density on the surface of hydrogel PRINT nanoparticles and
systematically observed the effects on protein adsorption, macrophage uptake, and circulation
time. Interestingly, the density of PEGylation necessary to promote a long-circulating particle was
dramatically less than what has been previously reported. Overall, our methodology provides a
rapid screening technique to predict particle behavior in vivo and our results deliver further insight
to what PEG density is necessary to facilitate long-circulation.
Keywords
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The full potential for nanotechnology has yet to surface even after decades of
groundbreaking research. Nano-based drug delivery systems have produced advancements
toward next generation cancer therapy (Doxil and Abraxane), but rapid elimination of
nanoparticles (NPs) from the body continues to mitigate progress.1–4 Following intravenous
(IV) administration, NPs are rapidly removed from circulation and accumulate mainly in the
liver and spleen due to opsonization and recognition by the mononuclear phagocyte system
(MPS).2,5–7 There have been many attempts to reduce uptake of nanoparticles by the MPS
by controlling the physicochemical characteristics of the particles, such as size, surface
charge, hydrophilicity, and surface functionality.2,5,8–10 Generally, nanoparticles that have a
mean diameter of 200 nm or less with a neutral to negative ζ-potential and an extended
hydrophilic polymer surface exhibit prolonged blood circulation.2,5,10,11
Poly(ethylene glycol) (PEG) has been extensively used on a variety of nanoparticle systems
to increase surface hydrophilicity and improve circulation half-life by decreasing
interactions with blood proteins and MPS cells.1,2,6,12–15 PEGylation can be conducted with
several unique techniques using diblock PEG derivatives, or by covalently attaching,
entrapping, or adsorbing PEG chains onto the surface of a nanoparticle.1,6,14 The effects of
PEGylation are highly dependent on the PEG molecular weight (MW), polymer chain
architecture, and surface density of the PEG coating, which leads to transitions in PEG
conformations at the surface.13,14,16 There is a general consensus that stealth properties can
be achieved by coating with a high density of PEG with MW ranging from 2K to
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10K.14,17–21 Despite PEG extending particle circulation in vivo, there is no general standard
as to what surface density is needed to accomplish this goal. This stems partially from a lack
of easy and efficient PEG quantification strategies.
A number of techniques are currently used to measure degree of PEGylation on NP surfaces,
yet few have reported precise techniques for PEG quantification on polymeric NPs.7 Most
techniques described in literature are qualitative assessments of PEGylation such as NMR
(PEG peak typically observed ~3.65 ppm), dynamic light scattering, and ζ-potential.22,23 In
some instances, PEG surface density is determined by simply assuming complete saturation
of PEG on the surface of the nanoparticle, and therefore surface PEG density is reported
based upon PEG size and nanoparticle surface area. For other nanoparticle formulations,
PEG is incorporated into the nanoparticle matrix and PEG surface coverage is then based
upon the weight or mole percent of the PEG incorporated, assuming that all the PEG chains
are on the surface and not embedded within the particle.14 Both of these methods typically
offer an overestimation of PEG grafting. Few quantitative methods exist to accurately
determine PEG surface density. Chromatography, such as size exclusion chromatography
(SEC) and high-performance liquid chromatography (HPLC), are well-documented
quantitation techniques for PEGylated liposomes.6,24 Thermogravimetric analysis (TGA) is
used to calculate PEG weight, but is restricted to metallic NPs.25 Surface plasmon resonance
(SPR) is another method to determine PEG loadings with the caveat that quantification is
generally characterized on flat substrates.7 X-ray photoelectron spectroscopy (XPS) and
Raman analyses can yield detailed information on conformation and quantification,
however, these methods are beyond typical analytical practices.7,21 Fluorescent assays are
commonly used for rapid PEG quantification and are amenable for a variety of nanoparticle
core compositions.7,24,26
PEGylation density is commonly described in terms of the conformation that surface-bound
PEG chains achieve, which is based upon the Flory radius (RF) of the PEG graft, the
distance (D) between PEG grafts, or the length/thickness (L) of the grafted PEG layer.7,27,28
Upon the basis of these parameters, there are two main conformations that PEG chains can
acquire, “mushroom” or “brush”.27,29,30 Mushroom conformation is dictated by having a
low density PEG coverage, where D > RF, and therefore the PEG chains are not fully
extended away from the nanoparticle surface, resulting in a thin PEG layer. As D decreases
to that of RF, PEG chains arrange in a brush conformation with the PEG chains extending
away from the nanoparticle surface, resulting in a thick layer. When L > 2RF, the brush
conformation was further defined by Damodaran et al. to be a dense brush.31 Thus by
knowing the three parameters, D, RF, and L, the conformation of the PEG chain can be
distinguished. Unfortunately, there is a disconnect throughout literature as to what
parameters are reported. For ease of comparing degree of PEGylation, we have compiled
data (Table 1) from the literature consisting of these key parameters and how they affect
protein binding, macrophage uptake and circulation half-life. Equations 1–3 and Supporting
Information S1–S2 were used to calculate unreported values (see Supporting Information for
details on calculations). Upon the basis of this compilation, it appears that the beneficial
effects of PEGylation (protein and macrophage rejection and enhanced circulation half-life)
occur when the PEG grafts are in the dense brush regime.
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The aim of this study was to evaluate PRINT hydrogel nanoparticles (80 nm × 80 nm × 320
nm) with varying PEG surface coverage. PEG conformation was determined through
standard plate-reader analysis of fluorescein-labeled PEG grafts. Herein we report predictive
screening methods that can rapidly asses the circulation fate of our PEGylated PRINT
nanoparticles. We explored the use of in vitro assays (protein binding and macrophage
uptake) to predict in vivo circulation behavior. Intravital microscopy was used to quickly
screen the circulation profiles of our particles, and a biodistribution study was conducted to
look at long time points and confirm the results of in vitro assays.
We synthesized calibration quality 80 nm × 80 nm × 320 nm hydrogel particles with a
narrow polydispersity index (PdI) on a continuous roll-to-roll lab line using the PRINT
process (Figure 1). Utilizing this roll-to-roll method, PRINT particles were successfully
made continuously at a rate of 360 mg/hour, which also resulted in highly uniform
populations of particles. Particles were fabricated with amine functional handles (from the
amino ethyl methacrylate), which were reacted with either a methoxy- or fluorescein-
terminated PEG5k-succinimidyl carboxy methyl ester (PEG5k-SCM). PEG grafting density
was controlled by varying the PEG5k-to-nanoparticle ratio, and was quantified by
fluorescence measurements of the fluorescein-PEG5k labeled particles. The fluorescence
signal was correlated to the concentration of fluorescein-PEG5k with a standard curve. PEG
density was calculated based upon the concentration of particles in solution and the surface
area of hydrated particles (equations can be found in Supporting Information). PEG density
was calculated to be 0.083 ± 0.006 and 0.028 ± 0.002 PEG/nm2 for the high and low PEG
density NPs, respectively (Figure 2). In these calculations for PEG density, we assumed a
uniform layer of PEG on the surface of the particle. Even though hydrogel particles swell,
leading to possible penetration into the particle, it is entropically unfavorable for a large
PEG molecule to permeate the hydrogel.
PEG density was converted to the area that one PEG chain occupies (A) and the distance
between PEG graft sites (D) was calculated (eq 3) to be 3.9 and 6.7 nm for the high and low
PEG density particles, respectively.32 As discussed in the introduction, the conformation of
the PEG grafts is dictated by the relationship between D and RF. The Flory radius (eq 1) is
determined by the number of monomers per polymer chain (N), and the length of one
monomer (α).29 For PEG5k, α = 0.35 nm and N = 113, therefore RF = 5.96 nm.33,34 Upon
the basis of RF and D, the PEG polymers were in the mushroom conformation for the low
PEG density NPs and in the brush conformation for the high PEG density NPs (Figure 3).
PEG brush thickness was calculated (eq 2) to be 7.9 ± 0.1 nm for high PEG density NPs.
Upon the basis of Damodaran criterion, the high PEG density NPs were not in the dense
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For all of the in vitro and in vivo studies, particles were PEGylated using the same method
outlined above but with a methoxy-PEG5k-SCM. Following PEGylation, the NPs were
acetylated to quench any remaining unreacted amines on the particle surface, resulting in
particles with a slightly negatively ζ-potential (Table 2). The acetylation reaction was
necessary because nanoparticles with positively charged surface groups typically exhibit
higher protein adsorption and cell association than neutral or negative groups.35–37 After
acetylation, particles were characterized by dynamic light scattering (DLS) and degree of
PEGylation was determined by fluorescence (Table 2). DLS was used to determine particle
hydrodynamic diameter (Dh), PdI, and ζ-potential (electrophoretic mobilities can be found in
Table S1 in Supporting Information). Dh values listed in the table are not indicative of
quantitative length scales and only act to compare relative trends between different particle
types. Calculations for D and L were based upon measuring particle dimensions from SEM
and AFM images (calculations can be found in Supporting Information).
It is well established that phagocytosis is facilitated by the adsorption of plasma proteins to
NP surfaces and that varying the surface chemistry of NPs can affect the identity and
amount of proteins adsorbed.15,35,36,38–40 One metric commonly used to characterize
“stealth” of PEGylated NPs is through in vitro classification including protein binding
and/or macrophage uptake experiments.14,19,21,36,39–46 In an effort to typify our PEGylated
PRINT nanoparticles, we conducted a comprehensive study of protein binding and
macrophage association on NPs with varying surface coverage of PEG.
Previous reports indicated that varying the surface chemistry of particles can affect both the
identity and amount of proteins adsorbed.35,36,46 Isothermal titration calorimetry (ITC) is the
gold standard for measuring biomolecular interactions and has recently been utilized to
determine nanoparticle–protein interactions.47–52 Following a protocol by Lindman and
coworkers, we used ITC to screen the effect that PEG conformation (mushroom vs brush)
had on protein adsorption.47 We investigated the interaction of bovine serum albumin (BSA)
with non-PEGylated, PEG mushroom, and PEG brush NPs. BSA was chosen as a model
protein because albumin is the most abundant protein in serum and is typically a major
component in the protein corona surrounding nanoparticles.14,35,36,53,54 The stoichiometry
of proteins bound per nanoparticle was derived from a simple fit to the data of a one-site
binding model using ORIGIN software (Figure 4 inset). Figure 4 shows the amount of
protein bound per particle significantly decreased with increasing surface PEG density.
These results support previous findings where an increase in surface PEG density leads to
decreased protein adsorption.14,42,43,46,55 However, in comparison to literature, we are
reporting protein rejection properties at much lower surface PEG density.14
The ITC studies clearly indicate that surface PEG density regulated the quantity of adsorbed
BSA, therefore we hypothesized that it would also regulate the efficiency of macrophage
uptake. To address macrophage association, nanoparticles were incubated in cell culture
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medium with the MH-S cells. Under these conditions, protein adsorption (from the cell
culture medium) onto the surface of the nanoparticles can lead to cellular recognition by the
macrophages and thus initiate uptake. We measured nanoparticle association with
macrophages as a function of PEG surface density and time (Figure 5). At early time points
(0.5 to 6 h) the PEG mushroom and PEG brush particles behaved the same and were
associated with MP-S cells 4–14 times less than non-PEGylated NPs. After 24 h, a slight
difference between the PEG mushroom and PEG brush NPs became evident. These findings
are in agreement with literature; as PEG surface coverage increases both protein adsorption
and macrophage association decreases.31,35,43,46 However, as shown in Table 1, these
protein/macrophage rejection properties are not typically observed until PEG grafts are in
the dense brush regime, whereas we observed these properties for both PEG mushroom and
PEG brush.
In an effort to translate in vitro data to circulation time in vivo, intravital microscopy (IVM)
was utilized to track fluorescent nanoparticles in the ear vasculature of anesthetized mice
over 2 h. Blood clearance curves of particles with varying surface PEG densities were
generated from IVM fluorescence measurements and are displayed in Figure 6. The data
plot clearly indicates that PEGylation is essential for extending circulation times. Both
mushroom and brush PEG particles appeared to have similar long-circulation profiles,
whereas the non-PEGylated particles were cleared rapidly. These findings are in line with
those observed from the macrophage assay, where the PEG mushroom and PEG brush NPs
exhibited nearly identical association.
In order to distinguish the difference between a mushroom and brush conformation, the
concentration of particles in blood at longer time points was investigated. Mice were dosed
with particles and sacrificed at certain time points extending out to 24 h. Figure 7 depicts
blood circulation curves with accompanying two-compartment PK model fits. The trend
among the particle types closely follows that of the IVM profiles. The non-PEGylated
particles exhibited the same rapid clearance. However, further delineation between a
mushroom and brush was displayed during the initial time points (>3 h), with a consistent
difference at 24 h.
Additionally, the MPS organs were resected and analyzed for particle fluorescence to
determine if organ accumulation was also dependent on surface PEG conformation. Figure 8
shows the organ accumulation as a function of PEG surface density at 24 h postinjection
(organ accumulation at earlier time points can be found in Supporting Information). The
blood concentration of non-PEGylated particles was undetectable at 24 h. Liver
accumulation was high for all particle types but showed decreased uptake as PEG density
increased. Furthermore, as PEG density increased, so did splenic uptake. This has been
observed for other PEGylated polymeric particles compared to non-PEGylated particles,
where a shift from liver to splenic accumulation was observed.19,56,57 It was hypothesized
that longer circulation times allow more exposure of the particles to the spleen, resulting in
higher splenic filtration and uptake by resident phagocytic cells.57 Our data fits this theory
with a marked increase in splenic fluorescence between non-PEGylated and PEGylated
particles, and a small increase as PEG density increased further. Thus, while PEGylation
increases circulation time via delayed phagocytosis, a particle’s fate is ultimately the MPS
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organs.19 While the exact mechanism is still unclear, this trend has been observed for over a
decade with many particle sizes, shapes, and compositions.1,5,14,30,58,59 Finally, lung and
kidney accumulation was minimal and likely attributed to fluorescence in residual blood
within the organ.
Pharmacokinetic (PK) parameters were determined from the blood concentration curves for
each particle type. Data was subjected to both one- and two-compartment analysis, with
elimination from the central compartment, using PKSolver. A two-compartment model was
found to be the best for all three particle types upon comparison of Akaike Information
Criterion values. Table 3 lists the secondary parameters calculated from the primary
constants of integration from the two-compartment model (Supporting Information Table
S2). As suggested by IVM data, PEGylation clearly extends particle circulation on longer
time scales. The half-life (beta-phase) increased from 0.89 h for non-PEGylated to 15.5 h for
PEG mushroom and 19.5 h for PEG Brush. Clearance and AUC (parameters important in
drug delivery applications) also increased as PEG density increased. A PEG brush surface
resulted in a 200-fold and 1.5-fold decrease in clearance versus a bare and PEG mushroom
surface, respectively. Significant improvements in PK values upon PEGylation are widely
cited in literature with similar results.14,57,59 Furthermore, longcirculation half-lives are
generally only observed for NPs with a dense PEG brush surface. Again, we have shown
these same improvements for NPs with PEG mushroom and brush surfaces.
We have developed a method for fabricating calibration quality hydrogel nanoparticles via a
continuous process. This allowed us to conduct comprehensive in vitro and in vivo studies
using highly uniform populations of particles and to fully characterize how NPs behave as a
function of surface PEG density. PEG density was varied using a highly tunable method that
could easily be quantified by fluorescence. Protein adsorption and macrophage association
were significantly reduced upon PEGylation of the NPs. An increase in PEG density,
resulting in a conformation change from mushroom to brush, showed slight improvements in
these in vitro studies. Extended circulation due to PEGylation was confirmed using IVM
with both PEGylated particles behaving similarly. Furthermore, a larger difference in
behavior between the two regimes became evident through PK and biodistribution analysis.
PEGylation resulted in at least a 17-fold increase in circulation half-life, a 136-fold decrease
in clearance, and an 86-fold increase in AUC over non-PEGylated NPs. In conclusion, we
show significant improvement in overall particle behavior with lower PEG densities than
previously reported.
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Scanning electron image of 80 nm × 80 nm × 320 nm PRINT hydrogel nanoparticles, scale
bar represents 500 nm. Dh, PdI, and ζ-potential were measured on a Malvern Zetasizer.
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PEG density quantification (n = 6) of 80 nm × 320 nm particles reacted with 14.0 and 2.0
mg of fluorescein-PEG5k-SCM resulting in brush (0.083 ± 0.006 PEG/nm2) and mushroom
(0.028 ± 0.002 PEGs/nm2) conformations, respectively. A control was conducted with 14.0
mg of deactivated fluorescein-PEG5k-SCM leading to a negligible PEG density.
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Cartoon representation of 80 nm × 80 nm × 320 nm PRINT hydrogel nanoparticles with
functionalized PEG in brush (A) and mushroom (B) conformations.
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Amounts of adsorbed BSA on non-PEGylated, PEG mushroom and PEG brush NPs. The
protein amount is expressed as mg BSA/m2 of NP surface area. Error bars represent standard
deviation for n = 3. The insert is a representative image raw data collected from the
isothermal titration calorimetry experiments.
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Percent of MH-S cells associated with non-PEGylated, PEG mushroom, and PEG brush
nanoparticles after various incubation times.
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Intravital microscopy circulation profiles based upon fraction of maximum fluorescence
remaining for non-PEGylated, PEG mushroom, and PEG brush nanoparticles.
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Concentration of nanoparticles in blood over time (open diamond, square, and triangle).
Data is fit to a two-compartment PK model (solid lines). Error bars represent standard
deviation for n = 4.
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Biodistribution of nanoparticles at 24 h postinjection, expressed as percent recovered
fluorescence per organ. Error bars represent standard deviation from n = 4.
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